Pregled bibliografske jedinice broj: 1258593
Assessment of platelet function during transcatheter aortic valve implantation
Assessment of platelet function during transcatheter aortic valve implantation // Cardiologia Croatica, Vol. 15, No. 3-4 (2020)
Zagreb: Hrvatsko kardiološko društvo, 2020. str. 59-59 doi:10.15836/ccar2020.59 (predavanje, međunarodna recenzija, prošireni sažetak, znanstveni)
CROSBI ID: 1258593 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Assessment of platelet function during
transcatheter aortic valve
implantation
(Assessment of platelet function during transcatheter
aortic valve implantation)
Autori
Ostojić, Zvonimir ; Samardžić, Jure ; Pavasović, Saša ; Šipuš, Dubravka ; Šafradin, Ivica ; Rešković Lukšić, Vlatka ; Šeparović Hanževački, Jadranka ; Skorić, Boško ; Miličić, Davor ; Bulum, Joško
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, prošireni sažetak, znanstveni
Izvornik
Cardiologia Croatica, Vol. 15, No. 3-4 (2020)
/ - Zagreb : Hrvatsko kardiološko društvo, 2020, 59-59
Skup
9th Croatian Conference on Interventional Cardiology - CROINTERVENT 2020
Mjesto i datum
Online; konferencija, 19.03.2020. - 22.03.2020
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
aortic stenosis ; transcatheter aortic valve implantation ; platelet reactivity ; antiplatelet therapy
Sažetak
Introduction: Recent studies described changes in platelet reactivity (PR) in days following transcatheter aortic valve implantation (TAVI).1 However, precise time course and duration of these changes have not been fully investigated. Aim of the study was to investigate PR changes during and after TAVI. Patients and Methods: Study included 40 consecutive patients with severe and symptomatic aortic stenosis undergoing transfemoral TAVI procedure. Patients’ clinical characteristics were collected from medical records. All patients who did not have chronic dual antiplatelet therapy received loading dose of aspirin and clopidogrel (300 mg) one day before the procedure followed by their standard maintenance doses. PR was measured in seven time points: before start of procedure (T1), after heparin administration (T2), 10 minutes after valve implantation (T3), at the end of procedure (T4), and on 3rd, 6th and 30th postoperative day (T5-7). PR was measured using impedance aggregometer in response to three platelet aggregation agonists using ASPI, ADP and TRAP test. Results: Mean patient age was 82.7 years with majority of patients being male 60% (N=25). All patients underwent successful transfemoral TAVI procedure using either self-expandable (N=25, 62.5 %) or balloon-expandable valve. Mean postimplantation gradient was 9.97±4.44 mmHg. More than mild paravalvular regurgitation persisted in 2 (5%) patients. Values of PR in each tested time point are presented in Table 1. There was no significant difference in PR between T1 and T2. After the valve implantation significant reduction of PR in all 3 tests was observed. PR continued to decline on consecutive measurements, with lowest values reached on 3rd post-TAVI day (T5). On T6, value of ASPI test were not significantly different to the ones measured on T1, while values of ADP and TRAP test remained significantly lower. By 30th post-TAVI day PR values reached levels not significantly different compared to T1. Conclusions: Presented results indicate that transfemoral TAVI induces transient decrease in PR regardless of the platelet activation pathway. Significant reduction of PR is observed 10 minutes after valve implantation with continuous decrease until 3rd day post-TAVI after which it is gradually increasing to pre-TAVI values.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Zvonimir Ostojić
(autor)
Boško Skorić
(autor)
Joško Bulum
(autor)
Jure Samardžić
(autor)
Davor Miličić
(autor)
Jadranka Šeparović-Hanževački
(autor)
Dubravka Šipuš
(autor)
Saša Pavasović
(autor)